Navigation Links
Lionbridge Receives ISO 13485:2003 Certification for Quality Management
Date:3/10/2009

Certification Underscores Lionbridge's Market-Leading Translation Management Program for Life Sciences Organizations Worldwide

WALTHAM, Mass., March 10 /PRNewswire-FirstCall/ -- Lionbridge (Nasdaq: LIOX) today announced that it recently received ISO 13485:2003 certification which verifies quality management systems for medical device companies. This certification expands Lionbridge's dedicated Life Sciences program and enhances the Company's translation management platform to adhere to the rigorous compliance requirements of its medical device clients. Lionbridge was awarded this certification as part of its Life Sciences Center of Excellence initiative, which provides specialized translation services to leading medical device companies, pharmaceutical companies, and contract research organizations around the world.

"This independent certification reflects our proven level of excellence in delivering translation services for medical device and life sciences organizations. As the market leader in translation, Lionbridge is committed to providing the highest levels of quality and service to ensure our clients meet and exceed their customers' expectations while adhering to strict regulatory compliance regulations," said Henri Broekmate, General Manager, Global Language and Content, Lionbridge. "Our clients can take advantage of our superior capabilities in translation and other services with the confidence of knowing our processes comply with the demanding requirements of ISO 13485."

ISO 13485:2003 is an internationally recognized quality standard that outlines particular quality management system requirements tailored to the manufacture of medical devices. ISO 13485:2003 specifies requirements for a quality management system where an organization needs to demonstrate its ability to provide medical devices and related services that consistently meet customer requirements and regulatory requirements applicable to medical devices and related services. The primary objective of ISO 13485:2003 is to facilitate harmonized medical device regulatory requirements for quality management systems. All requirements of ISO 13485:2003 are specific to organizations providing medical devices, regardless of the type or size of the organization.

Lionbridge's recent ISO 13485:2003 certification complements its existing ISO 9001-2000 certification.

About Lionbridge

Lionbridge Technologies, Inc. (Nasdaq: LIOX) is a leading provider of translation, development and testing services with FY 2008 revenue of $461 million. Lionbridge combines global resources with proven program management methodologies to serve as an outsource partner throughout a client's product and content lifecycle -- from development to translation, testing and maintenance. Global organizations rely on Lionbridge services to increase international market share, speed adoption of global products and content, and enhance their return on enterprise applications and IT system investments. Based in Waltham, Mass., Lionbridge maintains solution centers in 26 countries and provides services under the Lionbridge(R) and VeriTest(R) brands. To learn more, visit http://www.lionbridge.com.

    Contact: Sara Buda
             781-434-6190
             sara.buda@lionbridge.com


'/>"/>
SOURCE Lionbridge Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
2. IDM Pharmas MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
3. Huntington Hospital Cancer Center Receives Outstanding Achievement Designation
4. Takeda Receives New Information on Alogliptin (SYR-322) NDA
5. AED Receives Gates Foundation Grant to Improve Nutrition and Reduce Deaths Among Young Children in Developing Countries
6. MedX Health Receives CE Mark for Laser & Light Products
7. SpectraScience Receives FDA Clearance for Manufacturing Facility
8. ProteoTech Receives Funding From The Michael J. Fox Foundation for Parkinsons Disease Research to Develop Tools for Imaging Alpha-Synuclein Aggregation in Living Parkinsons Brain
9. Medical University of South Carolina Hollings Cancer Center Receives National Cancer Institute Designation
10. SynCare Receives Managed Health Services Contract Renewal
11. UIC receives $3 million to study prostate cancer risk factors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... Overland Park, KS (PRWEB) , ... June 27, 2016 , ... ... leader in retailers of Eyeglasses . , Millions of individuals in the United ... life, eyeglasses have become a way to both correct vision and make a fashion ...
(Date:6/26/2016)... , ... June 26, 2016 , ... PawPaws brand ... new product that was developed to enhance the health of felines. The formula is ... The two main herbs in the PawPaws Cat Kidney Support Supplement Soft ...
(Date:6/25/2016)... ... , ... Austin residents seeking Mohs surgery services, can now turn to Dr. ... Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include ... in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn ...
(Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... A recent ... that most people are unfamiliar with. The article goes on to state that individuals ... also many of these less common operations such as calf and cheek reduction. The ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... ANGELES , June 23, 2016 ... CAPR ), a biotechnology company focused ... therapeutics, today announced that patient enrollment in its ... in Duchenne) has exceeded 50% of its 24-patient ... enrollment in the third quarter of 2016, and ...
Breaking Medicine Technology: